CCM
EBS icon

Contrarian Capital Management’s Emergent Biosolutions EBS Stock Holding History

Contrarian Capital Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-40,000
Closed -$273K – 32
2024
Q2 		$273K Buy
+40,000
New +$172K 0.09% 27

Other funds holding EBS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OHA
Oak Hill Advisors New York $878M AUM 106.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Contrarian Capital Management's EBS Position: Q3 2024 in Review

Contrarian Capital Management sold out of Emergent Biosolutions (EBS) in Q3 2024, closing a stake of 40,000 shares — an estimated $273K sold.

Contrarian Capital Management first reported a position in EBS in Q2 2024 and held it in 1 quarter. The position peaked at $273K in Q2 2024. 140 funds tracked by Wall St. Rank hold EBS as of Q3 2024.

  • Contrarian Capital Management reported no remaining Emergent Biosolutions position as of Q3 2024 after selling out during the quarter.
  • Contrarian Capital Management sold 40,000 Emergent Biosolutions shares in Q3 2024, an estimated $273K.
  • Contrarian Capital Management first reported a position in Emergent Biosolutions in Q2 2024 and held it in 1 quarter.
  • Contrarian Capital Management's Emergent Biosolutions position peaked at $273K in Q2 2024.
  • 140 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2024.

Based on Contrarian Capital Management's 13F filing for Q3 2024, filed 13 Nov 2024.